Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Agnosia × Saline Solution × Clear all

Phase

Phase NA 3 Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Breast Neoplasms 9 Prostatic Neoplasms 4 Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Pain, Postoperative 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Fallopian Tube Neoplasms 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Lymphoma 2 Hemorrhage 2 Carcinoma, Renal Cell 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thromboembolism 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Peritoneal Neoplasms 1 Peripheral Nervous System Diseases 1 Pancreatic Cyst 1 Pain 1 Non-Muscle Invasive Bladder Neoplasms 1 Neurotoxicity Syndromes 1 Myofibroma 1 Multiple Myeloma 1 Metabolic Diseases 1 Melanoma 1

Interventions

Ketamine 3 Sodium Chloride 2 Ropivacaine 2 Propofol 2 Analgesics, Opioid 2 Analgesia, Patient-Controlled 2 parecoxib 1 Tea 1 Tapentadol 1 Surveys and Questionnaires 1 Sevoflurane 1 Saline Solution 1 Lidocaine 1 Ketorolac 1 Ibuprofen 1 Epinephrine 1 Dexamethasone 1 Codeine 1 Clonidine 1 Circumcision, Male 1 Celecoxib 1 Anesthesia, General 1 Acupuncture Therapy 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00210210 2025-09-19

KETAMINE

Institut Bergonié

Phase 3 Completed

230 enrolled 6 charts

Agnosia, Breast Neoplasms, Pain, Postoperative

Data powered by HemOnc (CC BY 4.0) Colophon ⚡